| 陈 波,张庆团,黄克锋,杨燕芬,熊弋平.瑞巴派特四联疗法对幽门螺杆菌阳性消化性溃疡患者血清氧化应激指标和胃蛋白酶原的影响[J].,2023,(11):2168-2172 |
| 瑞巴派特四联疗法对幽门螺杆菌阳性消化性溃疡患者血清氧化应激指标和胃蛋白酶原的影响 |
| Efficacy of Ouadruple Therapy of Rebamipide on Helicobacter Pylori Positive Peptic Ulcer and its Influence on Serum Oxidative Stress Index and Pepsinogen |
| 投稿时间：2022-10-21 修订日期：2022-11-17 |
| DOI：10.13241/j.cnki.pmb.2023.11.033 |
| 中文关键词: 瑞巴派特 四联疗法 幽门螺杆菌 消化性溃疡 疗效 氧化应激 胃蛋白酶原 |
| 英文关键词: Rebamipide Quadruple therapy Helicobacter pylori Peptic ulcer Efficacy Oxidative stress Pepsinogen |
| 基金项目:广西壮族自治区卫生健康委员会自筹经费课题（Z20200892） |
|
| 摘要点击次数: 455 |
| 全文下载次数: 292 |
| 中文摘要: |
| 摘要 目的：观察瑞巴派特四联疗法治疗幽门螺杆菌（Hp）阳性消化性溃疡的疗效及对患者血清氧化应激指标和胃蛋白酶原的影响。方法：选取2020年7月至2021年12月期间广西壮族自治区胸科医院收治的Hp阳性消化性溃疡患者（n=100），按照随机数字表法分为联合组（50例，瑞巴派特四联疗法）、对照组（50例，标准四联疗法）。对比两组疗效、量表评分、血清氧化应激指标、胃蛋白酶原（PG）、不良反应发生率、Hp根除率、复发率。结果：联合组的临床总有效率高于对照组（P<0.05）。联合组的消化性溃疡愈合率高于对照组（P<0.05）。治疗后，联合组胃食管反流性疾病症状频率量表（FSSG）各项评分、临床症状各项评分低于对照组（P<0.05）。治疗后，联合组血清丙二醛（MDA）低于对照组，血清谷胱甘肽过氧化物酶（GSH-PX）、超氧化物歧化酶（SOD）高于对照组（P<0.05）。治疗后，联合组胃蛋白酶原（PG）Ⅰ、PGⅡ低于对照组（P<0.05）。两组不良反应总发生率组间对比无差异（P>0.05）。联合组的Hp根除率高于对照组，复发率低于对照组（P<0.05）。结论：瑞巴派特四联疗法治疗Hp阳性消化性溃疡患者，可有效促进溃疡愈合，缓解临床症状，改善机体应激状态和胃蛋白酶原水平，提高Hp根除率，减少不良反应及复发情况。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the efficacy of ouadruple therapy of rebamipide on helicobacter pylori (Hp) positive peptic ulcer and its influence on serum oxidative stress index and pepsinogen. Methods: Patients with Hp-positive peptic ulcer(n=100) who were admitted to Chest Hospital of Guangxi Zhuang Autonomous Region from July 2020 to December 2021 were selected, and they were divided into combination group (50 cases, ouadruple therapy of rebamipide) and control group (50 cases, standard ouadruple therapy) according to random number table method. Efficacy, scoring scale, serum oxidative stress index, pepsinogen (PG), incidence of adverse reactions, Hp eradication rate and recurrence rate were compared in the two groups. Results: The total clinical effective rate in the combination group was higher than that in the control group(P<0.05). The healing rate of peptic ulcer in the combination group was higher than that in the control group(P<0.05). After treatment, the scores of the Symptom Frequency Scale of Gastroesophageal reflux disease(FSSG) and clinical symptoms in the combination group were lower than those in the control group(P<0.05). After treatment, serum malondialdehyde (MDA) in the combination group was lower than that in the control group, and serum glutathione peroxidase(GSH-PX) and superoxide dismutase (SOD) in the combination group were higher than those in the control group(P<0.05). After treatment, pepsinogen (PG)Ⅰand PGⅡin the combination group were lower than those in the control group (P<0.05). There was no difference in the total incidence of adverse reactions in the two groups(P>0.05). The Hp eradication rate in the combination group was higher than that in the control group, and the recurrence rate was lower than that in the control group(P<0.05). Conclusion: In the treatment of patients with Hp-positive peptic ulcer, ouadruple therapy of rebamipide can effectively promote ulcer healing, relieve clinical symptoms, improve the stress state of the body and the level of pepsinogen, increase the Hp eradication rate, reduce adverse reactions and recurrence. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
